Abstract |
Cefotiam, a new cephalosporin, was evaluated in the treatment of lower respiratory tract infections in 29 patients. The bacteria isolated from the sputum of these patients included Streptococcus pneumoniae (31%), Klebsiella pneumoniae (31%), and Haemophilus influenzae (28%). Satisfactory response was observed in 90% of the patients. There were three treatment failures, two superinfections, and four colonizations with gram-negative organisms resistant to the drug. Superficial phlebitis was noted in two patients. The results of this study suggest that cefotiam is an effective and well-tolerated antibiotic for the treatment of lower respiratory tract infections due to susceptible organisms.
|
Authors | M A Polis, C U Tuazon |
Journal | Antimicrobial agents and chemotherapy
(Antimicrob Agents Chemother)
Vol. 28
Issue 4
Pg. 576-7
(Oct 1985)
ISSN: 0066-4804 [Print] United States |
PMID | 3865632
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Cefotaxime
(analogs & derivatives, therapeutic use)
- Cefotiam
- Female
- Humans
- Male
- Middle Aged
- Respiratory Tract Infections
(drug therapy, microbiology)
|